
Oxford Nanopore has developed a new generation of nanopore-based sensing technology for faster, information-rich, accessible and affordable molecular analysis, used to understand and characterise the biology of humans and diseases such as cancer. By enabling biological insights, we strive to improve life on Earth and beyond.
We’re looking for a Senior Manager, Market Development EMEAI – Oncology to join our growing commercial team. In this role, the successful candidate will be responsible for driving commercial growth by expanding the total addressable oncology market for Oxford Nanopore Technologies across the EMEAI region. This role can be based in the UK, France, or Germany. Please note that this role involves frequent travel across EMEAI, minimum 50%.
This role focuses on identifying and unlocking new customer segments, applications, and geographies, translating ONT’s unique sequencing capabilities into scalable, commercially impactful market opportunities. Working at the intersection of science, policy, and commercial strategy, this role partners closely with sales, marketing, product, medical, regulatory, and government affairs teams to accelerate adoption and long‑term revenue growth.
This role has a primary focus on high-value applications in Oncology and where Oxford Nanopore Technologies offers clear differentiation. The role will identify and validate priority market opportunities, develop strategic partnerships and evidence-generation programs, and support the progression of promising applications from research-stage use through operationalization and production-scale deployment.
This role is suited to a highly self‑directed builder who thrives in ambiguous environments and can create momentum ahead of fully scaled organisational infrastructure.
Key Responsibilities and Duties:
Market Expansion & Growth
Partnerships, KOL & Ecosystem Development
Evidence Generation & Standards Shaping
Clinical, Regulatory & Market Access Alignment
Commercial Enablement & Cross‑Functional Leadership
Leadership & Capability Development
Please note that no terminology in this advert is intended to discriminate on the grounds of a person's gender, marital status, race, religion, colour, age, disability or sexual orientation. Every candidate will be assessed only in accordance with their merits, qualifications and abilities to perform the duties of the job.
#LI-JR1
#LI-hybrid
Oxford Nanopore Technologies: Our goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology for faster, information rich, accessible and affordable molecular analysis. The first application is DNA/RNA sequencing, and the technology is in development for the analysis of other types of molecules including proteins. The technology is used to understand and characterise the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses, and whole environments. With a thriving culture of ambition and strong innovation goals, Oxford Nanopore is a UK headquartered company with global operations and customers in more than 125 countries.

Our goal is to enable the analysis of anything, anywhere, by anyone.
We have developed the world’s first and only nanopore DNA and RNA sequencing platform. It’s a new generation of sequencing technology — the only one to offer: scalability to portable or ultra-high throughput formats, real-time data delivery, and the ability to elucidate rich biological data.
We are aiming to disrupt the way that biological analyses are currently performed, and open up new applications that have a profound, positive impact on society.
Our devices offer real-time analysis, for rapid insights, in fully scalable formats — from pocket to population scale — and the technology is being used in more than 100 countries worldwide.
Founded in 2005 as a spin-out from the University of Oxford, the company now employs more than 600 people from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialisation. The management team, led by CEO Dr Gordon Sanghera, has a track record of delivering disruptive technologies to the market.